EphMra

About us
Your are here:

Data & Systems

Catherine Beaucé (Chair)       Sanofi France
Markus Kaemmerer Abbott Products Operations AG  Switzerland 
Jackie Lord  AstraZeneca  UK
Petra Mannechez  Bayer Healthcare  Germany
Silke Behrendt Boehringer Ingelheim GmbH Germany
Jacky Gossage Glaxosmithkline UK
Karen Belentani Nycomed, a Takeda Company Switzerland
Stéphanie Coudiére Pierre Fabre Medicament France
Christopher Wooden Cegedim Strategic Data   UK
Alan Harrison IMS Health UK
Bridget Wiseman IMS Health UK

OBJECTIVES

Ensure databases & systems provide the best suitable platform to do international secondary market research through partnership with the major global providers.

ACTIVITIES

New 2011 : The Committee has decided to extend the scope of their activities to cover secondary data quality & coverage issues. In that perspective the Committee will focus on audits integrated on IMS & CSD international databases.

- Regular meetings with core providers IMS HEALTH & CEGEDIM STRATEGIC DATA to discuss their databases & systems offerings (quality, reliability & service associated) and main development pathways (meet business data requirements, address changing market dynamics or make the best use of latest technologies). They represent a key communication channel between global secondary data providers and international secondary market research functions from pharmaco’s.

- Share experiences & best practice in international secondary pharmaceutical market research area using any type of data : sales, medical or promotional.

- Identify current unmet needs of international pharmaceutical market research and share them with Syndicated Data Committee to cooperate on provider research.

The Committee consists of pharmaceutical international market research representatives and IMS & CSD representatives. Project teams may be formed to address specific needs and other providers may be invited to participate whenever appropriate. The Committee always welcomes new members from pharmaceutical industry to enlarge its knowledge & experience sharing.

Focus

Members :  12 to 15 pharmaco’s members would be the optimum to ensure good coverage of business needs, to maximize the sharing of experiences and to still allow open and constructive discussions with our Committee partnerships with IMS Health and CSD.

Membership of Committee is restricted to EphMRA full members, a limit of one member per company.  Seniority within a company is not an issue – all we ask is that members have a wide knowledge of IMS and/or CSD data & systems on an international basis (where international means more than 5 countries).

Meetings : The Committee meets twice a year. One meeting is organized within the frame of the yearly EphMRA conference and usually lasts 1.5 days. The second meeting is a one day interim meeting usually taking place in the first quarter of a year. The location for the interim meeting varies depending on the host.

Committee Poster 2011 - Find out more about the Committee's work

 

Your are here:
Back to top

Join our Linkedin group

Join the EphMRA Group, network and keep up to date.

Connect with us

© Copyright ©2012 EphMRA. All rights reserved.

Designed and developed by Merchant Marketing Group